BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 22639168)

  • 1. Active immunotherapy: oncolytic virus therapy using HSV-1.
    Todo T
    Adv Exp Med Biol; 2012; 746():178-86. PubMed ID: 22639168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
    Todo T
    Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Armed" oncolytic herpes simplex viruses for brain tumor therapy.
    Todo T
    Cell Adh Migr; 2008; 2(3):208-13. PubMed ID: 19262110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
    Shah AC; Parker JN; Gillespie GY; Lakeman FD; Meleth S; Markert JM; Cassady KA
    Gene Ther; 2007 Jul; 14(13):1045-54. PubMed ID: 17429445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.
    Fukuhara H; Ino Y; Kuroda T; Martuza RL; Todo T
    Cancer Res; 2005 Dec; 65(23):10663-8. PubMed ID: 16322208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors.
    Andreansky S; Soroceanu L; Flotte ER; Chou J; Markert JM; Gillespie GY; Roizman B; Whitley RJ
    Cancer Res; 1997 Apr; 57(8):1502-9. PubMed ID: 9108452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
    Todo T
    Hum Cell; 2002 Sep; 15(3):151-9. PubMed ID: 12703545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour-specific triple-regulated oncolytic herpes virus to target glioma.
    Delwar ZM; Liu G; Kuo Y; Lee C; Bu L; Rennie PS; Jia WW
    Oncotarget; 2016 May; 7(19):28658-69. PubMed ID: 27070093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
    Aghi M; Rabkin SD; Martuza RL
    Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Oncolytic virus therapy for malignant brain tumors].
    Ino Y; Todo T
    Brain Nerve; 2009 Jul; 61(7):815-22. PubMed ID: 19618859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic HSV-1 for the treatment of brain tumours.
    Markert JM; Parker JN; Buchsbaum DJ; Grizzle WE; Gillespie GY; Whitley RJ
    Herpes; 2006 Nov; 13(3):66-71. PubMed ID: 17147910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.
    Kolodkin-Gal D; Edden Y; Hartshtark Z; Ilan L; Khalaileh A; Pikarsky AJ; Pikarsky E; Rabkin SD; Panet A; Zamir G
    Gene Ther; 2009 Jul; 16(7):905-15. PubMed ID: 19440231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
    Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
    Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential application of a transcriptionally regulated oncolytic herpes simplex virus for human cancer therapy.
    Miao L; Fraefel C; Sia KC; Newman JP; Mohamed-Bashir SA; Ng WH; Lam PY
    Br J Cancer; 2014 Jan; 110(1):94-106. PubMed ID: 24196790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor.
    Kamiyama H; Zhou G; Roizman B
    Gene Ther; 2006 Apr; 13(7):621-9. PubMed ID: 16292350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses.
    Otsuki A; Patel A; Kasai K; Suzuki M; Kurozumi K; Chiocca EA; Saeki Y
    Mol Ther; 2008 Sep; 16(9):1546-55. PubMed ID: 18648350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic HSV therapy increases trametinib access to brain tumors and sensitizes them in vivo.
    Yoo JY; Swanner J; Otani Y; Nair M; Park F; Banasavadi-Siddegowda Y; Liu J; Jaime-Ramirez AC; Hong B; Geng F; Guo D; Bystry D; Phelphs M; Quadri H; Lee TJ; Kaur B
    Neuro Oncol; 2019 Sep; 21(9):1131-1140. PubMed ID: 31063549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.
    Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Martuza RL; Rabkin SD; Kurtz A
    Mol Ther; 2006 Dec; 14(6):789-97. PubMed ID: 17045531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors.
    Todo T; Rabkin SD; Martuza RL
    Cancer Gene Ther; 2000 Jun; 7(6):939-46. PubMed ID: 10880026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.
    Todo T; Martuza RL; Rabkin SD; Johnson PA
    Proc Natl Acad Sci U S A; 2001 May; 98(11):6396-401. PubMed ID: 11353831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.